A Message from the Director

Eva-Feldman-DirectorThree Years of Progress

Here at the Taubman Institute, we are building on the momentum of three productive and exciting years.

We currently are funding four Senior Taubman Scholars and eight Taubman Scholars, who with our and your support are doing groundbreaking research that will have profound effects on the understanding and treatment of a range of diseases.

We also are working to create the collaborative environment that is one of the cornerstones of the Institute, where the exchange of ideas and creative interaction across disciplines are vigorously promoted. 

This fall, for example, we kicked off our Visiting Professor lecture series with a presentation by Dr. Gary Landreth, a noted Alzheimer’s disease researcher from Case Western Reserve University.  The lectures are open to the campus and about 60 students, scientists and physicians gathered to hear Dr. Landreth – who, by the way, earned one of the first three doctorates granted by U-M’s Neuroscience program.

We also hold brown-bag lunches -- where members of all the Taubman labs get together to discuss their research – and the scholars regularly gather for “chalk talks” to share, discuss and debate their findings.

And we are poised to host our fourth annual Taubman Institute Symposium on October 14 in Ann Arbor, with presentations by new Taubman scholars and a keynote address by Michigan Gov. Rick Snyder.

Throughout the coming months, I invite your continued interest in the work of the Taubman Institute. To keep up with our research and news from the laboratories, please bookmark our website at www.taubmaninsitute.org.

This is a very exciting era in the search for treatments of some of the most devastating illnesses that strike individuals and families.  With the commitment of our scientists and the sustained support of people like Alfred Taubman, we are moving forward in our quest to challenge head-on some of today’s most deadly diseases.


Eva Feldman, M.D., Ph.D., FAAN
Director, Taubman Medical Research Institute
Professor of Neurology, University of Michigan Medical School


Help Us Make A Difference. Make A Donation That Could Save Lives.

Make A Gift


Follow Us / Friend Us

Discovery-driven research that matters


Taubman Scholar Dr. Charles Burant tests promising diabetes drug

TAK-875, a new treatment for type 2 diabetes, improves blood sugar control and is equally effective as glimepiride, but has a significantly lower risk of creating a dangerous drop in blood sugar, called hypoglycemia, according to a new study.

Read more

Taubman Institute leaders make the case for more doctor-scientist funding


The prestigious "Academic Medicine" journal has just published a new article authored by Taubman Institute senior management and Detroit-area attorney Scott Roberts.

The article explores the problematic gap between bench research and clinical application of new treatments or cures. 

Read more

Help Us Make A Difference. Make A Gift.

Leaders from the realms of business, academia and the community help to refine the Taubman Institute's vision, to monitor progress and to provide support, advice and counsel.

Meet the Leadership Advisory Board

Meet the Scientific Advisory Board

About Taubman Institute Video

In this video feature, Taubman Scholars explain why funding for high-risk research is so important to their work and to the discovery of promising cures and treatments.  


Stem cell surgery targets ALS Video

Patients glean hope from trial’s progress but wish it were faster


video-emerging-scholars-programDonors pitch in to keep brilliant science minds at U-M Video

Emerging Scholars program connects promising M.D.-researchers with philanthropists